1. Membrane Transporter/Ion Channel
  2. Monocarboxylate Transporter
  3. 7ACC1

7ACC1  (Synonyms: 香豆素D1421; DEAC; Coumarin D 1421; D 1421)

目录号: HY-D0067 纯度: 99.71%
COA 产品使用指南

7ACC1 (DEAC; Coumarin D 1421; D 1421) 是一种单羧酸转运蛋白 1 (MCT-1)/MCT-4 的特异性阻断剂。7ACC1 能够减弱肾癌细胞的增殖、迁移、侵袭,并下调 MCT1/MCT4 表达水平和细胞外乳酸的含量。7ACC1 有望用于癌症的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

7ACC1 Chemical Structure

7ACC1 Chemical Structure

CAS No. : 50995-74-9

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥178
In-stock
250 mg ¥162
In-stock
1 g ¥228
In-stock
5 g   询价  
10 g   询价  

* Please select Quantity before adding items.

Customer Review

    7ACC1 purchased from MCE. Usage Cited in: Cancer Med. 2018 Sep;7(9):4690-4700.  [Abstract]

    The protein expression of MCT4 in the murine breast cancer cell line 4T1 treated with 7ACC1 (0.1 mM) or transfected with different ShMCT4 vectors.

    查看 Monocarboxylate Transporter 亚型特异性产品:

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    7ACC1 (DEAC; Coumarin D 1421; D 1421) is a monocarboxylate transporter 1 (MCT-1)/MCT-4 specifc blocker. 7ACC1 attenuates renal cancer cell proliferation, migration, invasion and down-regulates the levels of MCT1/MCT4 expression and extracellular lactate. 7ACC1 is promising for research of cancers[1][2][3].

    IC50 & Target

    MCT1

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    4T1 IC50
    > 100 μM
    Compound: 7
    Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell proliferation by MTT assay
    Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell proliferation by MTT assay
    [PMID: 34626786]
    HepG2 IC50
    > 100 μM
    Compound: 10
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 28666736]
    MCF-10A IC50
    > 100 μM
    Compound: 7
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation by MTT assay
    [PMID: 34626786]
    MCF7 IC50
    > 100 μM
    Compound: 10
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 28666736]
    MDA-MB-231 IC50
    > 100 μM
    Compound: 10
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    [PMID: 28666736]
    MDA-MB-231 IC50
    > 100 μM
    Compound: 7
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation by MTT assay
    [PMID: 34626786]
    SiHa IC50
    0.86 μM
    Compound: 17
    Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 24 hrs by liquid scintillation counting
    Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 24 hrs by liquid scintillation counting
    [PMID: 24095010]
    SiHa EC50
    1.8 μM
    Compound: 17
    Cytotoxicity against human SiHa cells in lactate-containing medium after 72 hrs by MTT assay
    Cytotoxicity against human SiHa cells in lactate-containing medium after 72 hrs by MTT assay
    [PMID: 24095010]
    SiHa IC50
    250 nM
    Compound: 17
    Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 12 mins by liquid scintillation counting
    Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 12 mins by liquid scintillation counting
    [PMID: 24095010]
    SK-HEP1 IC50
    > 100 μM
    Compound: 10
    Antiproliferative activity against human SKHEP1 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SKHEP1 cells after 48 hrs by MTT assay
    [PMID: 28666736]
    WiDr IC50
    > 100 μM
    Compound: 7
    Antiproliferative activity against human WiDr cells assessed as inhibition of cell proliferation by MTT assay
    Antiproliferative activity against human WiDr cells assessed as inhibition of cell proliferation by MTT assay
    [PMID: 34626786]
    体外研究
    (In Vitro)

    7ACC1 (10 μM, 0-96 小时) 在 786-O 细胞和 HUVECs 的共培养条件下减弱了细胞的生存能力,降低了细胞迁移和侵袭能力[1]
    7ACC1 (10 μM, 24 小时) 抑制了 786-O 细胞与 HUVECs 共培养条件下 MCT1MCT4 的蛋白表达,降低了细胞外乳酸水平[1]
    7ACC1 (0-1 μM, 24 小时) 抑制癌细胞内乳酸的内流,但不影响外流[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[1]

    Cell Line: 786-O cells and HUVECs
    Concentration: 10 µM
    Incubation Time: 24 h
    Result: Attenuated the protein expressions of MCT1 and MCT4 in co-culturing of 786-O cells and HUVECs.
    体内研究
    (In Vivo)

    7ACC1 (3 mg/kg,腹腔注射,每日一次,持续 12 天) 能抑制在小鼠中表达 MCT 的宫颈 SiHa,结直肠 HCT116 和乳腺 MCF-7 肿瘤的生长[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: mice bearing tumors, including cervix cancer SiHa xenografts but also tumors derived from human colon cancer cells HCT116 and bladder cancer cells UM-UC3[2]
    Dosage: 3 mg/kg
    Administration: i.p., daily for 12 days
    Result: Led to significant SiHa and HCT116 tumor growth delays in mice bearing tumors.
    分子量

    261.27

    Formula

    C14H15NO4

    CAS 号
    性状

    固体

    颜色

    Orange to red

    Emission (Em)

    445

    Excitation (Ex)

    345

    中文名称

    香豆素D1421

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : 33.33 mg/mL (127.57 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 3.8275 mL 19.1373 mL 38.2746 mL
    5 mM 0.7655 mL 3.8275 mL 7.6549 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.5 mg/mL (9.57 mM); 悬浊液; 超声助溶

      此方案可获得 2.5 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.71%

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.8275 mL 19.1373 mL 38.2746 mL 95.6865 mL
    5 mM 0.7655 mL 3.8275 mL 7.6549 mL 19.1373 mL
    10 mM 0.3827 mL 1.9137 mL 3.8275 mL 9.5686 mL
    15 mM 0.2552 mL 1.2758 mL 2.5516 mL 6.3791 mL
    20 mM 0.1914 mL 0.9569 mL 1.9137 mL 4.7843 mL
    25 mM 0.1531 mL 0.7655 mL 1.5310 mL 3.8275 mL
    30 mM 0.1276 mL 0.6379 mL 1.2758 mL 3.1895 mL
    40 mM 0.0957 mL 0.4784 mL 0.9569 mL 2.3922 mL
    50 mM 0.0765 mL 0.3827 mL 0.7655 mL 1.9137 mL
    60 mM 0.0638 mL 0.3190 mL 0.6379 mL 1.5948 mL
    80 mM 0.0478 mL 0.2392 mL 0.4784 mL 1.1961 mL
    100 mM 0.0383 mL 0.1914 mL 0.3827 mL 0.9569 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    7ACC1
    目录号:
    HY-D0067
    需求量: